Non-Small Cell Lung Cancer (NSCLC): Molecular Markers, Immune Therapy and Targeted Therapy

Dear Colleagues,

Lung cancer is one of the most common forms of cancer and a major cause of cancer deaths globally, with Non-Small Cell Lung Cancer (NSCLC) being the most prevalent subtype. In recent decades, advances in molecular profiling and immuno-oncology have transformed the therapeutic landscape with novel predictive biomarkers, immune checkpoint inhibitors, and target-based therapies, leading to improved survival for select patient cohorts. However, the response to therapy and disease progression, as well as long-term outcome, is highly heterogeneous. Thus, studies addressing the biological, clinical, and translational features of NSCLC remain an urgent need.

NSCLC: Molecular Markers, Immune Therapy, and Targeted Therapy is a Special Issue that aims to provide a compilation of current data regarding novel targets and clinical approaches and highlight the role of precision medicine in early-stage, advanced, and metastatic disease settings. We welcome purification papers pertaining to molecular alterations such as EGFR, KRAS, ALK, MET, and ROS1, rare oncogenic driver mutations, and immune-based therapy, including checkpoint inhibition, neoadjuvant/adjuvant immunotherapy, and markers of immune solution/resistance response.

We welcome research that is particularly aligned with the journal, including, but not limited to, the following topics: artificial intelligence and predictive modelling, liquid biopsy and ctDNA assessment, radiogenomics, primary and acquired resistance mechanisms, and innovative real-world combination regimens. We particularly welcome translational work that has a basis in clinical translation.

This Special Issue welcomes original research articles, systematic and meta-analyses, clinical trials, translational studies, and high-quality narrative reviews. We strongly advocate for collaborations between surgeons, oncologists, radiologists, pathologists, and computational scientists.

Dr. Juliana Guarize
Guest Editor

Dr. Claudia Bardoni
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• NSCLC
• molecular markers
• targeted therapy
• immunotherapy
• precision oncology
• predictive biomarkers
• EGFR
• KRAS
• ALK
• liquid biopsy
• ctDNA
• resistance mechanisms
• radiomics
• real-world data
• neoadjuvant therapy
• adjuvant therapy